Darolutamide remains a critical therapy for patients with prostate cancer. However, clinicians must remain vigilant for emerging darolutamide safety signals identified in recent post-marketing surveillance. Therefore, researchers utilized the FDA Adverse Event Reporting System (FAERS) to conduct a comprehensive disproportionality analysis. Consequently, the study identified 11 positive signals at the system organ class (SOC) level and 62 signals at the preferred term (PT) level. These findings provide a granular safety assessment that extends beyond initial clinical trial data.

Understanding New Darolutamide Safety Signals

Specifically, the analysis highlighted several unexpected nervous system disorders that are not currently listed on the drug label. For example, reports indicated significant associations with peripheral neuropathy and brain fog. Furthermore, patients experienced ageusia, hypoesthesia, and difficulty in standing. Because these neurological events can significantly impact quality of life, early detection is essential. Moreover, healthcare providers should incorporate these potential risks into their routine clinical evaluations during the first few months of therapy.

Age-Specific Adverse Events and Monitoring

In addition to neurological concerns, the study observed distinct age-stratified risks. For instance, erectile dysfunction was more frequently reported in patients aged 18 to 64 years. In contrast, older patients over 65 years faced a statistically significant risk of multiple fractures. Meanwhile, the median time to the onset of these adverse events was just 30 days. Thus, the rapid onset suggests that the first month of treatment is a critical window for patient monitoring. Ultimately, these insights aid in more precise risk assessment and personalized care for cancer patients receiving darolutamide.

Frequently Asked Questions

What are the most common neurological darolutamide safety signals found?

The analysis identified peripheral neuropathy, brain fog, and ageusia as significant neurological signals that were previously unexpected and are not currently on the official drug label.

When do side effects usually appear after starting darolutamide?

The study reported that the median time to the onset of adverse events associated with darolutamide is approximately 30 days after starting the medication.

Are there different risks for older patients using darolutamide?

Yes, patients over 65 years of age showed a higher reporting rate for multiple fractures, while younger patients were more likely to report erectile dysfunction.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. While we strive for accuracy, drug safety data is constantly evolving. Always consult with a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Wu Z et al. Vigilance for drug safety of darolutamide in the cancer therapies: a disproportionality analysis from the FDA Adverse Event Reporting System. Naunyn Schmiedebergs Arch Pharmacol. 2026 Mar 26. doi: 10.1007/s00210-026-05253-5. PMID: 41886076.

Fizazi K, et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342.

Shore ND et al. Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115.